ReShape Lifesciences announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819, entitled, Intragastric Device. When issued, the patent will cover claims for an intragastric balloon system, comprising a capsule configured to be swallowable by a patient and to degrade in a gastric environment, with a balloon compacted and contained within the capsule, the balloon including an outer and inner surface, an interior cavity, a fill valve and release valve wherein the fill valve and release valves are separate valves, among other claim features. Once issued, the patent will provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1698 USD | -4.61% | +2.72% | -32.00% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 01 | Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.00% | 3.98M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- RSLS Stock
- News ReShape Lifesciences Inc.
- ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System